Zomedica Strengthens UK Market Position with Strategic Distribution Agreement for High-Growth Veterinary Innovation Portfolio
Zomedica (OTCQB:ZOMDF) has announced a strategic distribution partnership with Pioneer Veterinary Products Limited to strengthen its presence in the UK veterinary market. The agreement initially focuses on distributing Zomedica's TRUFORMA® diagnostic platform across England, Scotland, Wales, and Northern Ireland, with plans to later introduce VETGuardian® remote monitoring technology.
Pioneer will serve as an exclusive distributor for the small animal market and a non-exclusive distributor for equine products. The TRUFORMA platform provides reference lab-quality results for diagnosing endocrine and thyroid conditions in dogs, cats, and horses, while VETGuardian offers wireless, contactless monitoring of animal vitals in surgical and post-operative care settings.
Zomedica (OTCQB:ZOMDF) ha annunciato una partnership strategica di distribuzione con Pioneer Veterinary Products Limited per rafforzare la propria presenza nel mercato veterinario del Regno Unito. L'accordo prevede inizialmente la distribuzione della piattaforma diagnostica TRUFORMA® in Inghilterra, Scozia, Galles e Irlanda del Nord, con l'intenzione di introdurre successivamente la tecnologia di monitoraggio remoto VETGuardian®.
Pioneer agirà come distributore esclusivo per il segmento degli animali domestici e come distributore non esclusivo per i prodotti equini. La piattaforma TRUFORMA offre risultati di qualità da laboratorio di riferimento per la diagnosi di patologie endocrine e tiroidee in cani, gatti e cavalli, mentre VETGuardian fornisce monitoraggio wireless e senza contatto dei parametri vitali in ambito chirurgico e nel post-operatorio.
Zomedica (OTCQB:ZOMDF) ha anunciado una asociación estratégica de distribución con Pioneer Veterinary Products Limited para reforzar su presencia en el mercado veterinario del Reino Unido. El acuerdo se centra inicialmente en la distribución de la plataforma diagnóstica TRUFORMA® en Inglaterra, Escocia, Gales e Irlanda del Norte, con planes de introducir más adelante la tecnología de monitorización remota VETGuardian®.
Pioneer actuará como distribuidor exclusivo para el mercado de pequeños animales y como distribuidor no exclusivo para productos equinos. La plataforma TRUFORMA proporciona resultados de calidad de laboratorio de referencia para diagnosticar afecciones endocrinas y tiroideas en perros, gatos y caballos, mientras que VETGuardian ofrece monitorización inalámbrica y sin contacto de signos vitales en entornos quirúrgicos y de postoperatorio.
Zomedica (OTCQB:ZOMDF)는 영국 수의학 시장 내 입지를 강화하기 위해 Pioneer Veterinary Products Limited와 전략적 유통 파트너십을 발표했습니다. 이 합의는 우선 영국(잉글랜드, 스코틀랜드, 웨일스, 북아일랜드)에서 TRUFORMA® 진단 플랫폼의 유통에 중점을 두며, 이후 VETGuardian® 원격 모니터링 기술을 도입할 계획입니다.
Pioneer는 소동물 시장에서는 단독(독점) 유통업체로, 말(Equine) 제품군에서는 비독점 유통업체로 활동합니다. TRUFORMA 플랫폼은 개, 고양이 및 말의 내분비 및 갑상선 질환 진단을 위한 참조 실험실 수준의 결과를 제공하며, VETGuardian은 수술 및 수술 후 관리에서 동물의 활력징후를 무선·비접촉 방식으로 모니터링합니다.
Zomedica (OTCQB:ZOMDF) a annoncé un partenariat stratégique de distribution avec Pioneer Veterinary Products Limited afin de renforcer sa présence sur le marché vétérinaire du Royaume-Uni. L'accord porte initialement sur la distribution de la plateforme diagnostique TRUFORMA® en Angleterre, en Écosse, au Pays de Galles et en Irlande du Nord, avec l'intention d'introduire ultérieurement la technologie de surveillance à distance VETGuardian®.
Pioneer agira en tant que distributeur exclusif pour le marché des petits animaux et en tant que distributeur non exclusif pour les produits équins. La plateforme TRUFORMA fournit des résultats de qualité laboratoire de référence pour le diagnostic des affections endocriniennes et thyroïdiennes chez les chiens, les chats et les chevaux, tandis que VETGuardian propose une surveillance sans fil et sans contact des constantes vitales en contexte chirurgical et en post-opératoire.
Zomedica (OTCQB:ZOMDF) hat eine strategische Vertriebspartnerschaft mit Pioneer Veterinary Products Limited angekündigt, um seine Präsenz auf dem britischen Veterinärmarkt zu stärken. Die Vereinbarung konzentriert sich zunächst auf den Vertrieb der diagnostischen Plattform TRUFORMA® in England, Schottland, Wales und Nordirland, mit der Absicht, später die Fernüberwachungstechnologie VETGuardian® einzuführen.
Pioneer wird als exklusiver Vertriebspartner für den Kleintierbereich und als nicht-exklusiver Vertriebspartner für Produkte im Equine-Bereich fungieren. Die TRUFORMA-Plattform liefert Referenzlabor-Qualitätsergebnisse zur Diagnose von endokrinen und Schilddrüsenerkrankungen bei Hunden, Katzen und Pferden, während VETGuardian eine kabellose, berührungslose Überwachung der Vitalwerte in chirurgischen und postoperativen Bereichen bietet.
- Exclusive distribution agreement for small animal market in the UK
- Expansion into one of the world's most advanced veterinary markets
- Strategic partnership with a respected regional distributor
- Potential for additional Zomedica products to be included in the distribution agreement
- Non-exclusive distribution rights for equine products may limit market control
- Phased rollout approach means delayed introduction of VETGuardian technology
Insights
Zomedica's UK distribution agreement with Pioneer expands market reach for its diagnostic technologies, strengthening European presence and revenue potential.
Zomedica's new distribution partnership with Pioneer Veterinary Products represents a strategic market expansion that significantly enhances the company's footprint in the sophisticated UK veterinary market. The exclusive distribution agreement for the small animal segment and non-exclusive arrangement for equine products creates a structured pathway to penetrate one of Europe's most advanced veterinary markets.
The initial focus on distributing the TRUFORMA diagnostic platform—Zomedica's flagship point-of-care system for endocrine and thyroid conditions—followed by plans to introduce VETGuardian remote monitoring technology demonstrates a phased market entry strategy. This approach allows Pioneer to establish the brand's presence before introducing more complex monitoring technologies.
From a market development perspective, this partnership builds upon Zomedica's existing equine market presence in the UK while creating new opportunities in the larger small animal sector. The UK represents a particularly valuable market due to its high standards of veterinary care, substantial pet ownership rates, and willingness to invest in advanced veterinary diagnostics.
For Zomedica, this agreement could accelerate European market penetration by leveraging Pioneer's established distribution networks and local market knowledge—critical factors for success in fragmented international veterinary markets. The partnership model reduces the capital expenditure typically required for direct market entry while potentially accelerating revenue generation through an experienced local partner who understands regulatory nuances and practitioner preferences.
Strategic partnership with Pioneer Veterinary Products Limited expands Zomedica's presence in the UK veterinary market through distribution of its leading point-of-care solutions
ANN ARBOR, MI / ACCESS Newswire / September 3, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced a new distribution partnership in the United Kingdom with Pioneer Veterinary Products Limited, one of the region's most respected veterinary distributors. The agreement begins with the distribution of Zomedica's TRUFORMA® diagnostic platform throughout England, Scotland, Wales, and Northern Ireland, with the introduction of VETGuardian® remote monitoring technology planned at a later stage.
Under the agreement, Pioneer will lead sales and support for the small animal market on an exclusive basis and act as a non-exclusive distributor for equine products, expanding the availability of Zomedica's innovations across one of the world's most advanced veterinary regions.
The distributed products will initially include the TRUFORMA diagnostic platform, Zomedica's flagship point-of-care system delivering reference lab-quality results with point-of-care convenience for dogs, cats, and horses, supporting the diagnosis and monitoring of critical endocrine and thyroid conditions.
After the launch of the TRUFORMA line, Pioneer anticipates adding VETGuardian remote monitoring technology - a wireless, contactless system that continuously tracks animal vitals in real time, designed for high-efficiency monitoring in surgical and post-operative care, bringing best in class technology into the hands of veterinary professionals across the UK. "This agreement reflects another important step forward as we expand our distribution footprint in the UK," said Larry Heaton, Chief Executive Officer of Zomedica. "Building on our existing equine presence, this new partnership significantly increases access to our small animal solutions in one of the most influential veterinary markets in the world and supports our broader goal of global market leadership."
Clive Groombridge, Managing Director of Pioneer Veterinary Products Limited, commented: "We are delighted to partner with Zomedica to bring these advanced technologies to veterinary practices across the UK. Our team is passionate about supporting veterinary professionals with solutions that enhance patient care, and Zomedica's products fit perfectly with that mission."
Kevin Klass, Senior Vice President of Sales at Zomedica, added: "We're excited to launch this new partnership with a trusted UK distributor who shares our commitment to quality and innovation. As we move forward, we expect to include additional Zomedica products in this arrangement. The UK is a critical market, and we're confident that this relationship will accelerate our growth and support veterinary professionals in delivering outstanding care."
This new partnership strengthens Zomedica's European presence and brings veterinarians in the UK greater access to groundbreaking tools that improve animal outcomes and practice efficiency.
To learn more about the TRUFORMA® and VETGuardian® systems, or the full line of Zomedica's veterinary solutions, please visit www.zomedica.com.
For enquires in the UK, please reach out to Blake Anderson at blake.anderson@pioneervet.co.uk.
About Pioneer Veterinary Products Limited
Pioneer Veterinary Products is a family-owned supplier of quality veterinary equipment and consumables, dedicated to making life easier for busy practices and hospitals. Founded in 2004, our roots run deep in animal care- we combine traditional values with modern solutions. Our friendly, multi-skilled team is committed to providing reliable supply, expert advice, and tailored support to practices of all sizes-from independent clinics to nationwide groups.
With an extensive product range, dependable delivery, and bespoke CPD opportunities, we're here to keep veterinary teams equipped, informed, and focused on what matters most, providing outstanding patient care. Find out more at www.pioneervet.co.uk.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts:http://investors.zomedica.com
Facebook:https://m.facebook.com/zomedica
X (formerly Twitter):https://twitter.com/zomedica
Instagram:https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
What products will Zomedica (ZOMDF) distribute through Pioneer Veterinary in the UK?
What is the scope of Zomedica's distribution agreement with Pioneer Veterinary in the UK?
What does the TRUFORMA diagnostic platform by Zomedica do?
How does Zomedica's VETGuardian technology work?
Who should UK veterinarians contact about Zomedica's products?
